CSIMarket
 
Pacira Biosciences inc   (PCRX)
Other Ticker:  
 
 
Price: $29.4100 $0.15 0.513%
Day's High: $29.68 Week Perf: -5.19 %
Day's Low: $ 28.82 30 Day Perf: 0.62 %
Volume (M): 1,256 52 Wk High: $ 48.60
Volume (M$): $ 36,951 52 Wk Avg: $34.75
Open: $29.02 52 Wk Low: $25.93



 Market Capitalization (Millions $) 1,531
 Shares Outstanding (Millions) 52
 Employees 1,243
 Revenues (TTM) (Millions $) 666
 Net Income (TTM) (Millions $) 7
 Cash Flow (TTM) (Millions $) -486
 Capital Exp. (TTM) (Millions $) 43

Pacira Biosciences Inc
Pacira Biosciences Inc. is a specialty pharmaceutical company that focuses on developing and commercializing innovative drug therapies that enhance patient outcomes. The company's portfolio includes best-in-class regional anesthesia and analgesia products, as well as long-acting local anesthetic formulations for postoperative pain management.

The company was founded in 2006 as Pacira Pharmaceuticals, Inc. and is headquartered in Parsippany, New Jersey. It has grown rapidly in recent years, with a strong track record of clinical research and development, as well as a commitment to sustainability and social responsibility.

One of Pacira's flagship products is Exparel, a long-acting, liposome-based local anesthetic that provides up to 72 hours of pain relief following surgery. Exparel has been approved by the FDA for a wide variety of surgical procedures, and is considered a safe and effective alternative to traditional opioid-based pain management strategies.

Pacira's other products include DepoCyt(e), a chemotherapy drug for the treatment of lymphomatous meningitis, and iovera, a non-opioid, non-invasive pain management system that uses cold therapy to block nerve signals and provide pain relief.

In addition to its pharmaceutical products, Pacira is also committed to sustainability and social responsibility. The company has implemented several initiatives aimed at reducing its environmental impact, including a zero-waste program and efforts to minimize energy and water usage. It also supports a range of philanthropic causes, including organizations focused on cancer research and patient advocacy.

Overall, Pacira Biosciences Inc. is a cutting-edge pharmaceutical company that is pioneering innovative drug therapies for pain management and making significant progress in achieving sustainable and socially responsible business practices.


   Company Address: 5401 West Kennedy Boulevard, Suite 890 Tampa 33609 FL
   Company Phone Number: 553-6680   Stock Exchange / Ticker: NASDAQ PCRX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Pacira Study Proves EXPAREL as Sciatic Nerve Block Achieves Significant Pain Reduction and Reduces Opioid Consumption After Bunionectomy

Published Thu, Feb 15 2024 1:36 PM UTC

Pacira Releases Groundbreaking Study: EXPAREL as a Sciatic Nerve Block Revolutionizes Pain Management after BunionectomiesIn recent years, Pacira BioSciences has been at the forefront of developing innovative solutions to combat the significant challenges posed by postoperative pain management. Their latest groundbreaking study, which investigated the efficacy of EXPAREL as ...

Product Service News

Redefining Pain Management: A Closer Look at Pacira BioSciences' National Group Purchasing Agreement with Premier, Inc. for Non-opioid Solution, EXPAREL

Published Wed, Feb 7 2024 1:01 PM UTC

In an era marked by the opioid crisis, the need for reliable non-opioid pain management and regenerative health solutions has never been more urgent. Consequently, the annunciation of a national group purchasing agreement between Pacira BioSciences, Inc., and Premier, Inc. bears that significance. Pacira, a pioneering entity in the pharmaceutical industry, has secured this b...

Pacira Biosciences Inc

Pacira Biosciences Inc Breaks Through Adversity, Surges with Profitability in Q3 2023



Pacira Biosciences Inc surprised investors by achieving profitability in the third quarter of 2023, despite experiencing lower sales. The company reported earnings per share (EPS) of $0.23, showcasing its ability to navigate challenging market conditions. However, revenue declined by -2.114% to $163.93 million compared to the previous financial reporting period.
The decline in revenue sets Pacira Biosciences Inc apart from its peers in the Major Pharmaceutical Preparations sector, which witnessed revenue growth during the same period. In the preceding financial reporting period, the company reported a profit of $0.51 per share and a -3.27% decrease in revenue to $169.47 million.

Pacira Biosciences Inc

Pacira Biosciences Inc. sees 0.033% Quarterly Revenue Ascend, Notable Turnaround in Net Profit per Share for Q2 2023

Pacira Biosciences Inc is a pharmaceutical company that specializes in the development, manufacturing, and commercialization of innovative products for the acute care and ambulatory surgery markets. The company's focus is on providing non-opioid pain management solutions and improving patient outcomes.
In the second quarter of 2023, Pacira Biosciences Inc reported strong financial results, with net profit per share increasing by 27.5% to $0.51 compared to $0.40 in the same period the previous year. This growth in profit per share indicates the company's ability to generate higher earnings from its operations. Additionally, net profit per share turned positive from a loss of $0.43 per share in the preceding quarter, highlighting the company's improving financial performance.

Pacira Biosciences Inc

Pacira Biosciences Inc Reports Shortfall Despite Impressive Revenue Growth in Q1, 2023

Pacira Biosciences Inc, a pharmaceutical company specializing in developing and commercializing innovative therapies for patients, recently reported its financial results for the period closing March 31, 2023. According to the report, the company recorded a loss per stock of $-0.43 per share for the period, which is significantly higher than the loss of $0.15 per share reported in the same period a year before.
Moreover, the company's losses have grown from $-0.22 per share in the previous reporting season. This means that Pacira Biosciences Inc has been losing more money than it did in the past, which may cause concern among shareholders.






 

Pacira Biosciences Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com